Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 27 | 2024 | 3646 | 4.430 |
Why?
|
Sulfonamides | 10 | 2024 | 1984 | 1.670 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 1560 | 1.520 |
Why?
|
Trisomy | 2 | 2024 | 259 | 1.500 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 385 | 1.310 |
Why?
|
Asparaginase | 2 | 2024 | 240 | 1.040 |
Why?
|
Antibodies, Bispecific | 2 | 2023 | 203 | 0.850 |
Why?
|
Myelodysplastic Syndromes | 5 | 2024 | 1404 | 0.800 |
Why?
|
Staurosporine | 2 | 2021 | 240 | 0.770 |
Why?
|
Dioxygenases | 1 | 2024 | 354 | 0.760 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 309 | 0.730 |
Why?
|
fms-Like Tyrosine Kinase 3 | 6 | 2024 | 497 | 0.710 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 290 | 0.700 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 11868 | 0.690 |
Why?
|
Pyrazines | 2 | 2024 | 1204 | 0.670 |
Why?
|
Neutropenia | 2 | 2022 | 893 | 0.650 |
Why?
|
Depsipeptides | 1 | 2019 | 95 | 0.640 |
Why?
|
Cytarabine | 5 | 2024 | 698 | 0.630 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2019 | 125 | 0.590 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 196 | 0.570 |
Why?
|
Gastritis | 1 | 2019 | 200 | 0.560 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2023 | 679 | 0.550 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1050 | 0.510 |
Why?
|
Mutation | 10 | 2024 | 30198 | 0.460 |
Why?
|
Venous Thromboembolism | 2 | 2024 | 1882 | 0.440 |
Why?
|
Lymphoma | 1 | 2023 | 1897 | 0.440 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2024 | 5753 | 0.400 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4520 | 0.380 |
Why?
|
Prognosis | 11 | 2024 | 29922 | 0.360 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 1646 | 0.340 |
Why?
|
DNA Methylation | 1 | 2024 | 4424 | 0.330 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5696 | 0.330 |
Why?
|
Remission Induction | 4 | 2024 | 2411 | 0.310 |
Why?
|
DNA-Binding Proteins | 2 | 2024 | 9601 | 0.290 |
Why?
|
Aniline Compounds | 2 | 2024 | 1075 | 0.290 |
Why?
|
Humans | 52 | 2024 | 765968 | 0.280 |
Why?
|
Echocardiography | 1 | 2019 | 5045 | 0.260 |
Why?
|
Risk Assessment | 3 | 2023 | 24282 | 0.250 |
Why?
|
Leukemia | 2 | 2024 | 1522 | 0.240 |
Why?
|
Salvage Therapy | 2 | 2022 | 1272 | 0.230 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2024 | 42 | 0.220 |
Why?
|
Recurrence | 5 | 2024 | 8501 | 0.220 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13648 | 0.220 |
Why?
|
Daunorubicin | 1 | 2024 | 157 | 0.220 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4270 | 0.220 |
Why?
|
Chromosome Inversion | 1 | 2024 | 120 | 0.220 |
Why?
|
Idarubicin | 1 | 2023 | 59 | 0.220 |
Why?
|
p21-Activated Kinases | 1 | 2024 | 127 | 0.210 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2024 | 323 | 0.210 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2024 | 954 | 0.210 |
Why?
|
Sunlight | 1 | 2024 | 337 | 0.200 |
Why?
|
Young Adult | 8 | 2024 | 59889 | 0.190 |
Why?
|
Review Literature as Topic | 1 | 2023 | 297 | 0.190 |
Why?
|
Karyotyping | 1 | 2024 | 1178 | 0.190 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2022 | 185 | 0.190 |
Why?
|
Retrospective Studies | 16 | 2024 | 81514 | 0.180 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1927 | 0.170 |
Why?
|
Anemia, Aplastic | 1 | 2022 | 232 | 0.170 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 178 | 0.170 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2021 | 451 | 0.170 |
Why?
|
Azacitidine | 1 | 2021 | 334 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2022 | 252 | 0.160 |
Why?
|
Glucose-6-Phosphate | 1 | 2019 | 29 | 0.160 |
Why?
|
Adult | 16 | 2024 | 223044 | 0.160 |
Why?
|
Leukemia, Myeloid | 1 | 2022 | 696 | 0.160 |
Why?
|
Middle Aged | 18 | 2024 | 223009 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 722 | 0.160 |
Why?
|
ras Proteins | 1 | 2024 | 1053 | 0.160 |
Why?
|
Lymphoma, Follicular | 1 | 2023 | 459 | 0.160 |
Why?
|
Aged | 15 | 2024 | 171117 | 0.160 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1761 | 0.160 |
Why?
|
Aged, 80 and over | 9 | 2024 | 59489 | 0.150 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 230 | 0.150 |
Why?
|
Retreatment | 1 | 2019 | 598 | 0.150 |
Why?
|
Disease-Free Survival | 3 | 2023 | 6832 | 0.140 |
Why?
|
Adolescent | 7 | 2024 | 88835 | 0.140 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 180 | 0.140 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 689 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2020 | 443 | 0.130 |
Why?
|
Male | 18 | 2024 | 363698 | 0.130 |
Why?
|
Postoperative Complications | 1 | 2019 | 15747 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 647 | 0.130 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8529 | 0.130 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10261 | 0.130 |
Why?
|
Helicobacter pylori | 1 | 2019 | 380 | 0.120 |
Why?
|
Helicobacter Infections | 1 | 2019 | 390 | 0.120 |
Why?
|
Chromosome Aberrations | 1 | 2021 | 1774 | 0.120 |
Why?
|
Thrombocytopenia | 1 | 2022 | 1171 | 0.120 |
Why?
|
Survival Rate | 3 | 2024 | 12795 | 0.110 |
Why?
|
Methotrexate | 1 | 2020 | 1722 | 0.110 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1434 | 0.110 |
Why?
|
Disease Management | 1 | 2024 | 2535 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2942 | 0.110 |
Why?
|
Pyridones | 1 | 2019 | 816 | 0.110 |
Why?
|
Child | 5 | 2024 | 80564 | 0.100 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5783 | 0.100 |
Why?
|
Incidence | 4 | 2024 | 21480 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2024 | 2747 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3430 | 0.100 |
Why?
|
Abdominal Pain | 1 | 2019 | 1069 | 0.100 |
Why?
|
Bone Marrow | 1 | 2023 | 2921 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2136 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6499 | 0.100 |
Why?
|
Female | 15 | 2024 | 396112 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2444 | 0.100 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 2002 | 0.100 |
Why?
|
Dyspnea | 1 | 2019 | 1352 | 0.090 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3928 | 0.090 |
Why?
|
Pulmonary Artery | 1 | 2019 | 1935 | 0.090 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2233 | 0.090 |
Why?
|
Israel | 2 | 2023 | 725 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3850 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2033 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1946 | 0.070 |
Why?
|
Cyclopentanes | 1 | 2007 | 86 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2184 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5337 | 0.060 |
Why?
|
Cohort Studies | 4 | 2024 | 41649 | 0.060 |
Why?
|
Body Mass Index | 1 | 2023 | 13039 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5197 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 142 | 0.060 |
Why?
|
Melanoma, Experimental | 1 | 2007 | 558 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2007 | 616 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6547 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2024 | 65188 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5389 | 0.050 |
Why?
|
Oxidative Phosphorylation | 1 | 2024 | 502 | 0.050 |
Why?
|
Risk Factors | 3 | 2024 | 74840 | 0.050 |
Why?
|
Anthracyclines | 1 | 2023 | 284 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 13076 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39193 | 0.040 |
Why?
|
Signal Transduction | 1 | 2024 | 23601 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 5189 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2020 | 1061 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13451 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8041 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1731 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1608 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20659 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2019 | 596 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2024 | 3608 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1789 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2446 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22340 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1009 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2021 | 1635 | 0.030 |
Why?
|
Anticoagulants | 2 | 2021 | 4862 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2058 | 0.030 |
Why?
|
Causality | 1 | 2019 | 1248 | 0.030 |
Why?
|
Phosphorylation | 1 | 2024 | 8278 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2021 | 4860 | 0.030 |
Why?
|
Age Factors | 2 | 2019 | 18380 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2022 | 3715 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2023 | 2822 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2020 | 1203 | 0.020 |
Why?
|
Mitochondria | 1 | 2024 | 3673 | 0.020 |
Why?
|
Cell Line | 1 | 2024 | 15543 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3461 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3819 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26318 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1660 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5596 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4255 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4752 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14751 | 0.020 |
Why?
|
Oxylipins | 1 | 2007 | 55 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10603 | 0.020 |
Why?
|
Acetates | 1 | 2007 | 313 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15842 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10563 | 0.010 |
Why?
|
Cytokines | 1 | 2020 | 7421 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2007 | 720 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8703 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15398 | 0.010 |
Why?
|
Mice | 2 | 2024 | 81819 | 0.010 |
Why?
|
Stroke | 1 | 2019 | 9747 | 0.010 |
Why?
|
Animals | 2 | 2024 | 168764 | 0.010 |
Why?
|
Prospective Studies | 1 | 2019 | 54802 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 17075 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2007 | 22332 | 0.000 |
Why?
|